TechConnect Innovation Program

Tanibirumab, a fully human anti-VEGFR2 monoclonal antibody

PharmAbcine Inc, California, United States


Recently, Tanibirumab has been successfully completed in Phase I study in Korea. Under the controlling of clinical CRO, twenty-six Korean cancer patients were enrolled and treated with Tanibirumab. Considering main purpose of Phase I trial is to assess safety profile, we can have final report with stable data of toxicity.

Primary Application Area: Biotech & Biological Sciences

Technology Development Status: Proven Manufacturability

Technology Readiness Level: TRL 6


Value Proposition: Tanibirumab patent is registered on Korea, China, Japan, Singapore, EP and will be registered on USA, Canada, and Australia within a few months. Generally, some side effects like hypertension and blood breeding were commonly found in VEGF/VEGFR-2 signal blockers but there was no sign like those in Tanibirumab.


Organization Type: Mid-stage Startup (A or B)

National Innovation Awardee

Showcase Booth #: 904



Government Funding/Support to Date: We have received around $ 7 M of government grant since the Company establishment. Here is the list below.
1. Tanibirumab Grant ($ 1.5 M from Daejeon Techno Park, $ 0.7 M from Ministry of Health and Welfare, $ 2.1 M from Korea Drug Development Fund)
2. Bispecific antibody Grant ($ 0.4 M from Ministry of Health and Welfare, $ 1.7 M from Ministry of Knowledge and Economy, $ 0.3 M from Ministry of Knowledge and Economy)
3. Other Grant ($ 0.3 from Small and Medium Business Administration)

Primary Sources of Funding: Venture Capital

Looking for: Both Funding and Development Partners